BRPI0912703A2 - composições imuno-moduladoras e métodos para uso dessas - Google Patents

composições imuno-moduladoras e métodos para uso dessas

Info

Publication number
BRPI0912703A2
BRPI0912703A2 BRPI0912703A BRPI0912703A BRPI0912703A2 BR PI0912703 A2 BRPI0912703 A2 BR PI0912703A2 BR PI0912703 A BRPI0912703 A BR PI0912703A BR PI0912703 A BRPI0912703 A BR PI0912703A BR PI0912703 A2 BRPI0912703 A2 BR PI0912703A2
Authority
BR
Brazil
Prior art keywords
methods
immunomodulatory compositions
immunomodulatory
compositions
Prior art date
Application number
BRPI0912703A
Other languages
English (en)
Inventor
S Kohane Daniel
R Fink Gerald
Rubin-Bejerano Ifat
Original Assignee
Immunexcite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunexcite Inc filed Critical Immunexcite Inc
Publication of BRPI0912703A2 publication Critical patent/BRPI0912703A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
BRPI0912703A 2008-04-29 2009-04-29 composições imuno-moduladoras e métodos para uso dessas BRPI0912703A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7143708P 2008-04-29 2008-04-29
PCT/US2009/042117 WO2009134891A2 (en) 2008-04-29 2009-04-29 Immunomodulating compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0912703A2 true BRPI0912703A2 (pt) 2017-06-13

Family

ID=41255756

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912703A BRPI0912703A2 (pt) 2008-04-29 2009-04-29 composições imuno-moduladoras e métodos para uso dessas

Country Status (11)

Country Link
US (2) US8617823B2 (pt)
EP (1) EP2283358B1 (pt)
JP (2) JP2011519049A (pt)
CN (1) CN102119332A (pt)
AU (1) AU2009243094B2 (pt)
BR (1) BRPI0912703A2 (pt)
CA (1) CA2760044A1 (pt)
ES (1) ES2542066T3 (pt)
IL (1) IL208946A0 (pt)
MX (2) MX2010011788A (pt)
WO (1) WO2009134891A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0985149A1 (en) 1997-05-30 2000-03-15 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
WO2008057501A2 (en) 2006-11-06 2008-05-15 Whitehead Institute Immunomodulating compositions and methods of use thereof
US8617823B2 (en) 2008-04-29 2013-12-31 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
US20100111872A1 (en) * 2008-11-06 2010-05-06 University Of Saskatchewan System and method for modulating and optimizing immunotherapy
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
US10585098B2 (en) 2009-11-23 2020-03-10 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
US10288611B2 (en) * 2009-11-23 2019-05-14 The Johns Hopkins University Lateral flow device for diagnosing microbial infections
CA2807942C (en) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2012139089A2 (en) 2011-04-08 2012-10-11 The General Hospital Corporation Fungal-derived carbohydrate-conjugated scaffold
WO2012167061A1 (en) * 2011-06-03 2012-12-06 Biothera, Inc. OPSONIZED β-GLUCAN PREPARATIONS AND METHODS
EP2844262B1 (en) 2012-04-30 2018-01-10 Biothera, Inc. Beta-glucan immunotherapeutic preparation
IN2014DN10127A (pt) * 2012-06-05 2015-08-21 Nestec Sa
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN102901831B (zh) * 2012-10-25 2015-01-14 杭州宝康亿富生物科技有限公司 一种免疫调节多糖生物活性检测方法
WO2014159614A1 (en) * 2013-03-14 2014-10-02 Flow Pharma, Inc. Adjuvant and antigen particle formulation
CN104341409B (zh) * 2013-07-31 2017-11-28 北京勤邦生物技术有限公司 一种噻苯咪唑半抗原制备方法及其应用
JPWO2015068847A1 (ja) 2013-11-11 2017-03-09 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
EA201691168A1 (ru) * 2013-12-05 2016-11-30 Байотера, Инк. Способы исследования бета-глюкана
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
MX2016010835A (es) 2014-02-21 2017-07-11 Anokion Sa Terapeuticos dirigidos a la glucosa.
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10266609B2 (en) 2014-05-08 2019-04-23 Innate Biotherapeutics, Llc Immunomodulating beta-1,6-D-glucans
CN104072630B (zh) * 2014-07-11 2016-04-06 合肥工业大学 一种黄山石耳冷致凝胶多糖及其制备方法
EP3174541A1 (de) 2014-07-28 2017-06-07 Technische Universität Dresden Thymin- und chinazolin-dion-derivate zur hemmung von hsp27
US20170369570A1 (en) * 2015-01-20 2017-12-28 Immunexcite, Inc. Compositions and methods for cancer immunotherapy
WO2016196682A1 (en) 2015-06-01 2016-12-08 Immunexcite, Inc. β-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES
CN105879006A (zh) * 2016-02-01 2016-08-24 四川好医生攀西药业有限责任公司 一种治疗糖尿病足溃疡的药物组合物及其制备方法和应用
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN109415425A (zh) 2016-05-31 2019-03-01 财团法人牧岩生命科学研究所 TGF-β超家族的AB6家族设计配体
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
EP3279664A1 (en) * 2016-08-05 2018-02-07 Universität zu Köln Means and methods for detecting beta-1,6-glucan
WO2018024827A1 (en) * 2016-08-05 2018-02-08 Universität Zu Köln Means and methods for detecting beta-1,6-glucan
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
US11865135B2 (en) 2016-12-07 2024-01-09 Innate Biotherapeutics, Llc ß-1,6-glucan therapeutic antibody conjugates
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
KR102205829B1 (ko) * 2017-06-14 2021-01-21 기초과학연구원 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
US10946038B2 (en) * 2017-08-09 2021-03-16 Case Western Reserve University Cancer treatment using beta-(1-3)-(1-4)-glucan
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
CN113189315B (zh) * 2021-04-13 2024-01-23 山东省医疗器械产品质量检验中心 评价抗菌导尿管抗菌活性的体外动态模型及其使用方法
WO2024077042A2 (en) * 2022-10-05 2024-04-11 Onspira Therapeutics, Inc. Il-1 receptor antagonist treatment for neutrophilic lung disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480642A (en) * 1982-12-20 1996-01-02 The Board Of Regents Of The University Of Nebraska Synthetic immunoreglators, and methods of use and preparation
US4590181A (en) * 1982-12-20 1986-05-20 Board Of Regents Of The University Of Nebraska Synthetic immunoregulators and methods of use and preparation
US4739046A (en) 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
SE0203099D0 (en) * 2002-10-21 2002-10-21 A & Science Ab Publ Diagnosis of candidiasis and candidemia or invasive candida infection
WO2007033315A1 (en) 2005-09-14 2007-03-22 Whitehead Institute For Biomedical Research Drug induced exposure of the fungal pro-inflammatory molecule beta-glucan
US7732187B2 (en) * 2006-04-17 2010-06-08 Intervet Inc. Recombinant attenuated clostridium organisms and vaccine
WO2008057501A2 (en) 2006-11-06 2008-05-15 Whitehead Institute Immunomodulating compositions and methods of use thereof
US8617823B2 (en) 2008-04-29 2013-12-31 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof

Also Published As

Publication number Publication date
IL208946A0 (en) 2011-01-31
EP2283358B1 (en) 2015-04-22
CA2760044A1 (en) 2009-11-05
WO2009134891A2 (en) 2009-11-05
US8617823B2 (en) 2013-12-31
CN102119332A (zh) 2011-07-06
ES2542066T3 (es) 2015-07-30
US20140308238A1 (en) 2014-10-16
MX2010011788A (es) 2011-05-30
AU2009243094A1 (en) 2009-11-05
EP2283358A4 (en) 2011-09-07
US20110177532A1 (en) 2011-07-21
JP5959589B2 (ja) 2016-08-02
MX343525B (es) 2016-11-09
US9005903B2 (en) 2015-04-14
EP2283358A2 (en) 2011-02-16
WO2009134891A3 (en) 2010-02-18
JP2011519049A (ja) 2011-06-30
AU2009243094B2 (en) 2015-02-12
JP2015004690A (ja) 2015-01-08

Similar Documents

Publication Publication Date Title
BRPI0912703A2 (pt) composições imuno-moduladoras e métodos para uso dessas
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0920284A2 (pt) composição e método
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0911297A2 (pt) composição e métodos para preparo e uso das mesmas
BRPI0814594A2 (pt) Composições e métodos adjuvantes de antígeno
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
BRPI0821668A2 (pt) Uso
DK2337521T3 (da) Midlertidig embolibeskyttelsesindretning
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0906749A2 (pt) Composição
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI1007494A2 (pt) composto e uso do mesmo
IT1392101B1 (it) Composizione comprendente isoflavoni
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BRPI0917205A2 (pt) vacina polivalente
BRPI1005670A2 (pt) composições adjuvantes e métodos de uso
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
BRPI0913424A2 (pt) composições agrícolas de baixa taxa de uso e métodos para o uso
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes
BRPI0920891A2 (pt) misturas de alfa-amilase e métodos para uso das referidas misturas
BRPI1008326A2 (pt) Composições e métodos para controlar nanatódeos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]